SCHEMBL959281

SCHEMBL959281

CCC(Br)[C](Br)Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7871147 0.76
SCHEMBL931673 0.73
SCHEMBL3628379 0.73
SCHEMBL7475439 0.73
SCHEMBL962287 0.73
SCHEMBL7872855 0.71
SCHEMBL16970009 0.71
SCHEMBL4303823 0.69
SCHEMBL11267933 0.67
SCHEMBL23775550 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4382100-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS Eurofarma Laboratórios S.A. (BR) 2024-06-12 EP disclosed
CN-118076348-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 CN disclosed
WO-2023149548-A1 NOVEL PHARMACEUTICAL COMPOSITION 国立大学法人富山大学 2023-08-10 WO disclosed
WO-2023149549-A1 NOVEL PHARMACEUTICAL COMPOSITION 国立大学法人富山大学 2023-08-10 WO disclosed
WO-2023097386-A1 SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS EUROFARMA LABORATÓRIOS S.A (BR) 2023-06-08 WO disclosed
WO-2023010191-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2023-02-09 WO disclosed
US-9611258-B2 Dual MEK/PI3K inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-04-04 US disclosed
EP-2968345-A1 DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME The Regents of The University of Michigan (US) 2016-01-20 EP disclosed
US-20160002212-A1 DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2016-01-07 US disclosed
WO-2014164942-A1 DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-10-09 WO disclosed
US-6410587-B1 FIBROSIS; ALZHEIMER'S DISEASE; ANTIARTHRITIC AGENTS NEORX CORPORATION 2002-06-25 US disclosed
EP-0745594-B1 PROCESS FOR PRODUCING 6-SUBSTITUTED 2(1H)-QUINOXALINONE NISSAN CHEMICAL IND LTD (JP) 2001-05-09 EP disclosed
US-6117911-A ADMINISTRATION OF AT LEAST ONE THERAPEUTIC AGENT THAT ELEVATES THE LEVEL OF TGF-BETA IN SAID MAMMAL. NEORX CORPORATION (US) 2000-09-12 US disclosed
WO-1998046588-A2 COMPOUNDS AND THERAPIES FOR THE PREVENTION OF VASCULAR AND NON-VASCULAR PATHOLOGIES NEORX CORPORATION (US) 1998-10-22 WO disclosed
US-5786479-A Process for producing a 6-subsitituted 2(1H)-quinoxalinone NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1998-07-28 US disclosed
EP-0745594-A1 PROCESS FOR PRODUCING 6-SUBSTITUTED 2(1H)-QUINOXALINONE NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1996-12-04 EP disclosed
US-4628048-A Organosilyl compounds fungicidal compositions and use BASF AKTIENGESELLSCHAFT (DE) 1986-12-09 US disclosed
US-4579842-A Organosilyl compounds and their use as fungicides BASF AKTIENGESELLSCHAFT (DE) 1986-04-01 US disclosed
EP-0093274-B1 ORGANOSILYL COMPOUNDS AND THEIR USE AS FUNGICIDES BASF Aktiengesellschaft (DE) 1985-07-24 EP disclosed
EP-0093274-A1 Organosilyl compounds and their use as fungicides BASF Aktiengesellschaft (DE) 1983-11-09 EP disclosed